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Abstract
A simple, sensitive and rapid spectrophotometric method was developed and validated for the determination of
two skeletal muscle relaxants namely, tizanidine hydrochloride (I) and orphenadrine citrate (II) in pharmaceutical
formulations. The proposed method is based on the formation of a binary complex between the studied drugs
and eosin Y in aqueous buffered medium (pH 3.5). Under the optimum conditions, the binary complex showed
absorption maxima at 545 nm for tizanidine and 542 nm for orphenadrine. The calibration plots were rectilinear
over concentration range of 0.5-8 μg/mL and 1-12 μg/mL with limits of detection of 0.1 μg/mL and 0.3 μg/mL for
tizanidine and orphenadrine respectively. The different experimental parameters affecting the development and
stability of the complex were studied and optimized. The method was successfully applied for determination of
the studied drugs in their dosage forms; and to the content uniformity test of tizanidine in tablets.
Introduction
Tizanidine hydrochloride or 5-Chloro-N-(2-imidazolin-
2-yl)-2,1,3-benzothiadiazol-4-ylamine hydrochloride(1-3),
is a centrally acting skeletal muscle relaxant. It is an a2-
adrenergic agonist that acts mainly at spinal and
supraspinal levels to inhibit excitatory interneurones. It
is used for the symptomatic relief of spasticity associated
with multiple sclerosis or with spinal cord injury or dis-
ease. It is also used in the symptomatic treatment of
painful muscle spasm associated with musculoskeletal
conditions [1]. The United States Pharmacopoeia (USP)
recommends HPLC method for determination of tizani-
dine (I) in the raw material and tablets [4]. Additionally,
a number of methods like spectrophotometry [5-12],
voltammetry [13-15], GC [16,17], TLC [18-20] and
HPLC [12,18,21-24], have been reported in the literature
for the determination of tizanidine hydrochloride.
Orphenadrine citrate (II) or N, N-dimethyl-2-[(2-
methylphenyl) phenylmethoxy] ethanamine [3], is
employed as skeletal muscle relaxant [2]. The recom-
mended method for determination of orphenadrine in
USP [4] is HPLC while the British Pharmacopoeia (BP)
recommends a potentiometric titration procedure for its
assay of the raw material [25]. Several methods for
determination of Orphenadrine in pharmaceutical for-
mulations have been described, via spectrophotometry
[26-30], GC [31], capillary electrophoresis [32-35], TLC
[36] and HPLC [37-39].
The formation of complexes between eosin Y as an
ion pairing agent and many pharmaceutical compounds
for their spectrophotometric or spectrofluorimetic analy-
sis with or without metal ions has been frequently inves-
tigated [40-45].
The method suggested is devoted to study the forma-
tion of a binary complex between each of the studied
drugs and eosin Y in an attempt to develop a simple,
sensitive and accurate extraction- free spectrophoto-
metric method for the determination of the studied
drugs in their pharmaceutical preparations.
Experimental
Apparatus
A Shimadzu recording Spectrophotometer (UV-1601, P/
N 206-67001) with 1-cm matched cells was used.
Materials and reagents
All materials used were of Analytical Reagent grade, and
doubly distilled water was used throughout the work.
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were kindly provided by Sigma Pharmaceutical Com-
pany, Cairo, Egypt, they were used as received.
- Eosin Y (Merck, Darmstadt, Germany), 4 × 10
-3 M
aqueous solution was prepared in distilled water.
- Acetic acid and anhydrous sodium acetate (Merck,
Darmstadt, Germany).
- Acetate buffer, 0.4 M was prepared by mixing var-
ious volumes of 0.4 M acetic acid and 0.4 M sodium
acetate solutions to obtain the required pH value.
-Sirdalud
® Tablets (labeled to contain 2 mg and 4 mg
of tizanidine hydrochloride), Norflex
® Tablets (labeled
to contain 100 mg of orphenadrine citrate) and Norflex
®
ampoules (labeled to contain 30 mg of orphenadrine
citrate/ml) were obtained from commercial sources in
the local market.
Standard solutions
-S t o c ks o l u t i o n so f1 0 0 . 0μg/mL for (I) or (II) drugs
were prepared by dissolving 10.0 mg of either drug in
100 mL of distilled water. These solutions were stable
for at least a week when kept in the refrigerator and
protected from light. More dilute solutions were
obtained by appropriate dilution.
Procedures for calibration graph
Transfer accurately measured aliquots of the stock
solution in the concentration range shown in table 1
into a series of 10 mL volumetric flasks and diluted to
about 7 mL with distilled water. 1 mL for (I) and 0.7
mL for (II) of 4 × 10
-3 M of eosin Y solution was
added to each flask, and the solutions were mixed well
before the addition of 2 mL of 0.4 M acetate buffer
(pH 3.5). the solution completed with distilled water to
the mark. The absorbance was measured at 545 or 542
nm for (I) or (II) respectively against an appropriate
reagent blank prepared simultaneously. To get the
standard calibration graphs, the values of the absor-
bance were plotted against the final concentration in
μg/mL, alternatively the regression equations were
derived.
Procedures for determination of the studied drugs in
dosage forms
Tablets
An accurately weighed quantity of the mixed contents of
10 pulverized tablets equivalent to 10.0 mg of either
drug were transferred into 100 mL volumetric flasks,
and completed to the mark with distilled water. The
contents of the flask were sonicated for 15 min and fil-
tered, and the above procedu r ew a sf o l l o w e d ,t h en o m -
inal contents were calculated either from the previously
plotted calibration graphs or using the corresponding
regression equations.
Ampoules
An accurately measured volume of the mixed contents
of 10 ampoules equivalent to 10.0 mg of orphenadrine
citrate were transferred into 100 mL volumetric flask,
and diluted to 100 mL with distilled water. The above
procedure was followed; the nominal contents were cal-
culated adopting the standard addition method.
Determination of the stoichiometry of the reaction
The stoichiometry of the reaction between the studied
drugs and eosin Y was determined by continuous varia-
tion method (Job’s method) [46], using equimolar solu-
tions (1.5 × 10
-3 M) for (I) and (1 × 10
-3 M) for (II) of
the drug and the reagent.
Results and Discussion
Eosin Y was chosen as an ion-pairing agent with the
aim of obtaining stable and water soluble ion pairs
whose absorbance would be measured accurately. The
described method has the advantage of being simple,
fast, accurate, and precise for determining tizanidine
and orphenadrine in their pharmaceutical formula-
tions without interference from common excipients.
Moreover, it is less time-consuming and does not
require various elaborate treatment or tedious extrac-
tion procedures. These, in addition to the satisfactory
sensitivity and simplicity make the method suitable
for routine analysis in quality control laboratories.
The proposed method is based on binary complex for-
mation between the studied drugs and eosin Y. These
complexes were probably formed via electrostatic inter-
action between the most basic center in the drug
Table 1 Analytical parameters for the analysis of the
studied drugs by the proposed spectrophotometric
method
Parameter
(a) Tizanidine(I) Orphenadrine(II)
Wavelength(nm) 545 542
Concentration range(μg/mL) 0.5-8 1-12
Limit of detection (LoD) (μg/mL) 0.1 0.3
Limit of quantification(LoQ)
(μg/mL)
0.26 0.95
Correlation coefficient 0.9999 0.9998
Slope 0.12 0.09
Intercept 0.11 0.032
Sy/x 5.43 × 10
-3 0.013
Sa 3.2 × 10
-3 8.84 × 10
-3
Sb 7.06 × 10
-4 1.29 × 10
-3
RSD,% 1.20 1.60
% Error 0.45 0.64
ε (l/mol./cm.) 4.26 × 10
4 4.63 × 10
4
(a) Sy/x: standard deviation of the residuals; Sb: standard deviation of the
slope,
%Error = % RSD/√n; Sa, standard deviation of the intercept; and ε, molar
absorptivity.
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the dye. This primarily occurs in an acidic solution,
increasing the electron delocalization of eosin and pro-
ducing a bathochromic shift of the dye about 30 nm
(Figure 1), Applying Job’sm e t h o d( F i g u r e2 ) ,i tw a s
found that, the reaction proceeds in the ratio of 1:2 of
drug to eosin for tizanidine as it has two basic centers
and while 1:1 for orphenadrine as it has one basic center
of drug to eosin Y, the proposed mechanism of the reac-
tion pathway is shown in Figure 3.
Due to the slight solubility of complexes formed with
eosin Y in aqueous acidic solutions, it was difficult for
the produced color to be accurately and precisely mea-
sured. Therefore, several tria l sf o rs o l v i n gt h i sp r o b l e m
were conducted, Via extraction with organic solvent [47]
or addition of nonionic surfactant such as methyl cellu-
lose to solubilize and stabilize the formed complex were
attempted [40,41].
Methyl cellulose and tween 80 were attempted to pre-
vent complex precipitation, however the reproducibility
Figure 1 Absorption spectra. (A) Blank eosin Y (4 × 10
-3 M) in water (_ _ _). (B) Eosin Y binary complex with tizanidine hydrochloride (5 μg/
mL) in water at pH 3.5 (–). (C) Eosin Y binary complex with orphenadrine citrate (5 μg/mL) in water at pH 3.5 (......).
(B)                      (A)    
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0.00
0.25
0.50
0.75
1.00
Mole fraction of Tizanidine
A
b
s
o
r
b
a
n
c
e
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Mole fraction of Orphenadrine
A
b
s
o
r
b
a
n
c
e
Figure 2 Continuous variation plots for the ion association complexes. (A) Tizanidine hydrochloride (1.5 × 10
-3 M) with eosin Y (1.5 × 10
-3
M). (B) Orphenadrine citrate (1 × 10
-3 M) with eosin Y (1 × 10
-3 M).
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by El-Brashy et al [42] was adopted. This method is
based on keeping the sample concentration at maximum
dilution before adding thed y es o l u t i o na tn e u t r a l
solution, and mixing well before the addition of the
acidic buffer. Applying this procedure, the complex sta-
bility was greatly increased, and prevention of precipi-
tate formation with maximum precision was achieved.
Cl
N
S
N
NH
N
H
N +  2
pH 3.5
Cl
N
S
N
+NH2
N
-
 2
O HO
Br
Br Br
Br
COOH
O
O HO
Br
Br Br
Br
COO
O
+NH2
+
pH 3.5
-
O HO
Br
Br Br
Br
COOH
O
O HO
Br
Br Br
Br
COO
O
N
CH3 O
CH3
CH3
+NH
CH3
O
CH3
CH3
Figure 3 Proposed mechanisms for the reaction between tizanidine and orphenadrine with eosin Y. (A) Proposed mechanism for the
reaction between tizanidine and eosin Y. (B) Proposed mechanism for the reaction between orphenadrine and eosin Y.
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essential for good precision. The proposed method has
been successfully applied for determination of tizanidine
and orphenadrine in their tablets and ampoules while
the ampoules required application of standard addition
method as it contains sodium hydroxide which causes
significant decrease in the absorbance value [4], Applica-
tion of standard addition method succeed to remove the
interference of additives in the ampoules.
Optimization of experimental conditions
Factors affecting the complex formation and stability
were carefully studied and optimized.
1 - Effect of pH
The influence of pH on the absorbance value of the bin-
ary complexes was studied over the pH range 2.6-4.5,
Adjustment to pH 5 give negative absorbance values.
T h eo p t i m u ma b s o r b a n c ev a l u e sw e r eo b t a i n e da tp H
3.5 for both drugs as shown in Figure 4. Two milliliters
of 0.4 M acetate buffer were sufficient to bring the opti-
mum pH value. For the highest color intensity and max-
imum precision, the buffer solution should be added
after mixing the drug-dye solution at neutral pH.
2 - Effect of concentration of reagent
The optimum reagent concentration was determined by
adding various volumes of 4 × 10
-3 Me o s i nYs o l u t i o n .
It was found that 1 mL and 0.7 mL of the reagent solu-
tion for tizanidine and orphenadrine respectively give
the highest absorbance values as shown in Figure 5.
3 - Effect of temperature
The intensity of the final color was maximum at room
temperature for both drugs; increasing temperature
resulted in formation of a precipitate which may be due
to coagulation of the formed complex.
4 - Effect of time
The formation of the complex was instantaneous and
the development of the color was complete within few
seconds. The high values of the formation constants Kf
=2 . 6 9×1 0
11 for tizanidine while for orphenadrine Kf =
4.77 × 10
4reveals high stability of the formed complex,
the negative value of ΔG=- 6 . 5 2×1 0
4 and -2.67 × 10
4
(KJ/mole) for tizanidine and orphenadrine respectively,
points to the spontaneous nature of the reaction [48].
The intensity of the final color was stable for 48 hours
with no precipitation of the complex.
Method validation
Linearity and range
The calibration graphs obtained by plotting the absor-
bance values versus the final concentration were found
to be rectilinear over the concentration range cited in
table 1. Linear regression analysis of the data gave the
following equations:
−Fortizanidine : A = 0.108 + 0.124C (r = 0.9999)
−Fororphenadrine : A = 0.032 + 0.093C (r = 0.9998)
Where (A) is the absorbance, (C) is the concentration in
μg/ml and (r) is the correlation coefficient. Statistical ana-
lysis of the data gave small values of the standard devia-
tions of the residuals (Sy/x), the standard deviation of the
intercept (Sa), the standard deviation of the slope (Sb), and
the percentage of relative error (% Er) as shown in table 1.
Limit of quantification and limit of detection
The limit of quantification (LoQ) was determined by
establishing the least concentration that can be
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Figure 4 Effect of pH of 0.4 M acetate buffer on the absorbance of the reaction product of tizanidine or orphenadrine with eosin Y (4
×1 0
-3 M).
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[49], below which the calibration range is non linear, it
was found to be 0.27 μg/mL for tizanidine and 0.95 μg/
mL for orphenadrine. The limit of detection (LoD) was
determined by evaluating the lowest concentration of
the analytes that can be readily detected and was found
to be 0.1 and 0.3 μg/mL for tizanidine and orphena-
drine, respectively. The LoQ and LoD were calculated
according to the following equations (ICH 2005):
LoQ = 10Sa/b
LoD = 3.3Sa/b
Where (Sa) is the standard deviation of the intercept
of the regression line and (b) is the
slope of the calibration curve.
Accuracy and precision
To prove the accuracy of the proposed method, the
results of the assay of the studied drugs in pharmaceuti-
cal preparations were compared with the reference
methods [4], the statistical analysis [50] of the results
using student’s t-test and variance ratio F-test showed
no significant differences between them regarding accu-
racy and precision, tables 2 and 3.
Intraday and interday precisions were assessed using
three concentrations and three replicates of each con-
centration, the relative standard deviations were found
to be very small indicating reasonable repeatability of
the proposed method as shown in table 3.
Robustness
T h er o b u s t n e s so ft h ep r o c e d u r ea d o p t e di nt h ep r o -
posed method is demonstrated by the constancy of the
absorption intensity with minor changes in the experi-
mental parameters such as the change of the pH of
acetate buffer 3.5 ± 0.2 for both drugs and volume of
eosin 0.7 ± 0.2 and 1 ± 0.5 for orphenadrine and tizani-
dine respectively. These minor changes that may take
place during the experimental operation did not affect
the absorption intensity indicating the excellent robust-
ness of the proposed method.
Specificity
The specificity of the method was investigated by obser-
ving any interference encountered from the common
excipients of the pharmaceutical formulations. It was
found that these compounds did not interfere with the
results of the proposed method as shown in table 2.
Applications
I - Dosage form analysis
The proposed method was successfully applied to the
assay of tizanidine and orphenadrine in their dosage
forms as shown in table 2. The average percent recov-
eries of different concentrations were based on the aver-
age of three replicate determinations. The results
obtained were in good agreement with those obtained
by the reference methods [4].
II - Content uniformity test
Due to the high sensitivity of the proposed method for
the determination of tizanidine the content uniformity
t e s tw a sa p p l i e d .T h es t e p so ft h et e s tw e r ea d o p t e d
according to the USP [4] procedures. The acceptance
value (AV) was calculated and it was found to be smal-
ler than the maximum allowed acceptance value. The
results demonstrated excellent drug uniformity as
shown in table 4.
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Figure 5 Effect of volume of eosin Yon the absorbance of the reaction product of tizanidine or orphenadrine with eosin Y (4 × 10
-3 M).
Walash et al. Chemistry Central Journal 2011, 5:60
http://journal.chemistrycentral.com/content/5/1/60
Page 6 of 9Table 2 Application of proposed method to the determination of the studied drugs in their dosage forms.
Preparation Proposed method Reference method[4]
Conc. added
(μg/mL)
Conc. found
(μg/mL)
Recovery (%) Conc.added
(μg/mL)
Recovery(%)
Sirdalud
® tablets 2.0 2.02 101.00 40.0 99.40
(2 mg tizanidine hydrochloride/tablet) 4.0 3.98 99.50 80.0 100.50
8.0 8.03 100.37 100.0 100.60
X ±S D 100.29 ± 0.75 (found amount = 2.005 mg/tablet) 100.20 ± 0.66
t 0.21 (2.77)
F 1.28 (19)
Sirdalud
® tablets 2.0 2.03 101.5 40.0 99.90
(4 mg tizanidine hydrochloride/tablet) 4.0 4.00 100.00 80.0 98.50
8.0 7.96 99.50 100.0 100.20
X ±S D 100.33 ± 1.04 (found amount = 4.013 mg/tablet) 99.53 ± 0.91
t 1.00 (2.77)
F 1.31(19)
Norflex
® tablets (100 mg orphenadrine citrate/tablet) 5.0 4.99 99.90 20.0 98.79
10.0 9.87 98.70 50.0 100.55
12.0 12.11 100.90 100.0 98.99
X ±S D 99.83 ± 1.10 (found amount = 99.83 mg/tablet) 99.44 ± 0.96
t 0.46 (2.77)
F 1.31 (19)
Norflex
® ampoules (30 mg orphenadrine citrate/mL) 3.0 2.95 98.30 20.0 98.76
5.0 5.10 102.00 50.0 98.00
10.0 10.07 100.70 100.0 100.30
X ±S D 100.33 ± 1.87 (found amount = 30.099 mg/mL) 99.02 ± 1.17
t 1.03 (2.77)
F 2.56 (19)
*Note. Each result is the average of three separate assays.
*Values between brackets are the tabulated t and F values at p = 0.05
Table 3 Accuracy and precision data for the studied drugs using the proposed method.
Tizanidine
Parameter Intra-day precision Inter-day precision
Concentration taken
(mg/mL)
Concentration found
(mg/mL)
% Found Concentration taken
(mg/mL)
Concentration found
(mg/mL)
% Found
Data 2.0 2.02 101.00 2.0 2.01 100.50
4.0 3.99 99.83 4.0 4.003 100.10
8.0 7.9 99.62 8.0 7.99 99.90
X ±S D 100.15 ± 0.74 100.20 ± 1.28
%RSD 0.74 1.3
%Error 0.43 0.75
Orphenadrine
Parameter Intra- day precision Inter- day precision
Concentration taken
(mg/mL)
Concentration found
(mg/mL)
% Found Concentration taken
(mg/mL)
Concentration found
(mg/mL)
% Found
Data 3.0 2.99 99.66 3.0 2.97 99.00
5.0 4.99 99.86 5.0 5.01 100.20
12.0 12.08 100.66 12.0 12.02 100.16
X ±S D 100.06 ± 0.53 99.78 ± 0.68
%RSD 0.53 0.68
%Error 0.31 0.39
(a) Each result is the average of three separate experiments
X = The mean recovery; SD Standard deviation of results.
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Page 7 of 9Conclusion
A Simple, sensitive, fast, accurate and precise specto-
photometric method was developed for the determina-
tion of tizanidine and orphenadrine in their
pharmaceutical formulations with limit of quantification
of 0.26 μg/mL for tizanidine and 0.95 μg/mL for orphe-
nadrine. Eosin Y was chosen as an ion- pairing agent
with the aim of obtaining stable and water soluble ion
pairs whose absorbance would be measured accurately.
The advantage of the method being less time consuming
and do not require various elaborate treatments and
tedious extraction procedures, In addition to the satis-
factory sensitivity and reproducibility as well as the con-
venience and simplicity.
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